Patent ID: 9352047
Filing Date: 2016-05-31
CPC Classification: A61J,A61K,A61P,B65D,C07B,C09K

Claim Text:
1. An oral transmucosal dosage form comprising (a) a primary vehicle comprising wherein the testosterone is combined with the CIA to form the primary vehicle, and wherein the CIA reduces the crystallinity of the testosterone by at least 50% as measured by DSC relative to essentially pure testosterone not combined with the CIA; and (b) a secondary vehicle comprising wherein said oral transmucosal dosage form weighs about 250 mg to about 5000 mg, said oral transmucosal dosage form erodes in about 5 to about 60 minutes, but does not disintegrate, and said oral transmucosal dosage form is solid at 37 ° C.